Lupin is currently trading at Rs. 897.00, up by 16.55 points or 1.88% from its previous closing of Rs. 880.45 on the BSE.
The scrip opened at Rs. 889.80 and has touched a high and low of Rs. 910.00 and Rs. 889.80 respectively. So far 69179 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1090.00 on 30-Oct-2017 and a 52 week low of Rs. 723.55 on 15-May-2018.
Last one week high and low of the scrip stood at Rs. 910.00 and Rs. 833.50 respectively. The current market cap of the company is Rs. 40566.29 crore.
The promoters holding in the company stood at 47.00%, while Institutions and Non-Institutions held 37.69% and 15.30% respectively.
Lupin’s wholly owned subsidiary in US -- Lupin Pharmaceuticals -- has partnered with the American Sexual Health Association (ASHA) and the National Association of Nurse Practitioners in Women's Health (NPWH) to conduct a two-pronged national online survey among women who have been diagnosed with bacterial vaginosis (BV) and healthcare providers (HCPs) who treat women with the condition.
According to an online survey, although HCPs report sharing crucial information on BV with patients, the associated risks of the condition remain a mystery to many women, indicating a significant disconnect.
Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.
